CLINICAL RESEARCH: CLINICAL TRIAL
Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With AspirinThe Randomized, Double-Blind OCLA (Omeprazole CLopidogrel Aspirin) Study
Martine Gilard, MD*,*,
Bertrand Arnaud, PharmD ,
Jean-Christophe Cornily, MD*,
Grégoire Le Gal, MD ,
Karine Lacut, MD ,
Geneviève Le Calvez, PharmD ,
Jacques Mansourati, MD*,
Dominique Mottier, MD ,
Jean-François Abgrall, MD ,1 and
Jacques Boschat, MD*,1
* Department of Cardiology, Brest University Hospital, Brest, France
Department of Hematology, INSERM 0502, Brest University Hospital, Brest, France
Center for Clinical Investigation, EA3878, Brest University Hospital, Brest, France
Department of Internal Medicine and Chest Diseases, Brest University Hospital, Brest, France.
Manuscript received March 19, 2007;
revised manuscript received June 7, 2007,
accepted June 12, 2007.
* Reprint requests and correspondence: Dr. Martine Gilard, Département de Cardiologie, CHU de la Cavale Blanche, Boulevard Tanguy Prigent, 29609 Brest Cédex, France. (Email: martine.gilard{at}chu-brest.fr).
Objectives: This trial sought to assess the influence of omeprazole on clopidogrel efficacy.
Background: Clopidogrel has proved its benefit in the treatment of atherothrombotic diseases. In a previous observational study, we found clopidogrel activity on platelets, tested by vasodilator-stimulated phosphoprotein (VASP) phosphorylation, to be diminished in patients receiving proton pump inhibitor (PPI) treatment.
Methods: In this double-blind placebo-controlled trial, all consecutive patients undergoing coronary artery stent implantation received aspirin (75 mg/day) and clopidogrel (loading dose, followed by 75 mg/day) and were randomized to receive either associated omeprazole (20 mg/day) or placebo for 7 days. Clopidogrel effect was tested on days 1 and 7 in both groups by measuring platelet phosphorylated-VASP expressed as a platelet reactivity index (PRI). Our main end point compared PRI value at the 7-day treatment period in the 2 groups.
Results: Data for 124 patients were analyzed. On day 1, mean PRI was 83.2% (standard deviation [SD] 5.6) and 83.9% (SD 4.6), respectively, in the placebo and omeprazole groups (p = NS), and on day 7, 39.8% (SD 15.4) and 51.4% (SD 16.4), respectively (p < 0.0001).
Results: Omeprazole significantly decreased clopidogrel inhibitory effect on platelet P2Y12 as assessed by VASP phosphorylation test. Aspirin-clopidogrel antiplatelet dual therapy is widely prescribed worldwide, with PPIs frequently associated to prevent gastrointestinal bleeding. The clinical impact of these results remains uncertain but merits further investigation. (OCLA: Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated to Aspirin; http://www.clinicaltrials.gov/ct2/show/NCT00349661; NCT00349661
[ClinicalTrials.gov]
)
|
Abbreviations and Acronyms
| | ADP = adenosine diphosphate | | MFI = mean fluorescence intensity | | PPI = proton pump inhibitor | | PRI = platelet reactivity index | | SD = standard deviation | | VASP = vasodilator-stimulated phosphoprotein |
|
Related Articles
-
Omeprazole: A Possible New Candidate Influencing the Antiplatelet Effect of Clopidogrel
- Paul A. Gurbel, Wei C. Lau, and Udaya S. Tantry
J. Am. Coll. Cardiol. 2008 51: 261-263.
[Full Text]
[PDF]
-
Inside This Issue of JACC
J. Am. Coll. Cardiol. 2008 51: A37-A38.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
G. Dangas, R. Mehran, G. Guagliumi, A. Caixeta, B. Witzenbichler, J. Aoki, J. Z. Peruga, B. R. Brodie, D. Dudek, R. Kornowski, et al.
Role of Clopidogrel Loading Dose in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Angioplasty: Results From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
J. Am. Coll. Cardiol.,
October 6, 2009;
54(15):
1438 - 1446.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Rudez, H. J. Bouman, J. W. van Werkum, F. W.G. Leebeek, A. Kruit, H. J.T. Ruven, J. M. ten Berg, M. P.M. de Maat, and C. M. Hackeng
Common Variation in the Platelet Receptor P2RY12 Gene Is Associated With Residual On-Clopidogrel Platelet Reactivity in Patients Undergoing Elective Percutaneous Coronary Interventions
Circ Cardiovasc Genet,
October 1, 2009;
2(5):
515 - 521.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Nikolsky, G. W. Stone, A. J. Kirtane, G. D. Dangas, A. J. Lansky, B. McLaurin, A. M. Lincoff, F. Feit, J. W. Moses, M. Fahy, et al.
Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
J. Am. Coll. Cardiol.,
September 29, 2009;
54(14):
1293 - 1302.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Cuisset, C. Frere, J. Quilici, R. Poyet, B. Gaborit, L. Bali, O. Brissy, P.-E. Morange, M.-C. Alessi, and J.-L. Bonnet
Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study.
J. Am. Coll. Cardiol.,
September 22, 2009;
54(13):
1149 - 1153.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Schomig
Ticagrelor -- Is There Need for a New Player in the Antiplatelet-Therapy Field?
N. Engl. J. Med.,
September 10, 2009;
361(11):
1108 - 1111.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Wallentin
P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use
Eur. Heart J.,
August 2, 2009;
30(16):
1964 - 1977.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Verstuyft, T. Simon, and R. B. Kim
Personalized medicine and antiplatelet therapy: ready for prime time?
Eur. Heart J.,
August 2, 2009;
30(16):
1943 - 1963.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Schomig, N. Sarafoff, and M. Seyfarth
Triple antithrombotic management after stent implantation: when and how?
Heart,
August 1, 2009;
95(15):
1280 - 1285.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. R. Holmes Jr, D. J. Kereiakes, N. S. Kleiman, D. J. Moliterno, G. Patti, and C. L. Grines
Combining Antiplatelet and Anticoagulant Therapies.
J. Am. Coll. Cardiol.,
July 7, 2009;
54(2):
95 - 109.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Varenhorst, S. James, D. Erlinge, J. T. Brandt, O. O. Braun, M. Man, A. Siegbahn, J. Walker, L. Wallentin, K. J. Winters, et al.
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
Eur. Heart J.,
July 2, 2009;
30(14):
1744 - 1752.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. A. Dakik and K. Barada
Adverse Outcomes Associated With Use of Proton Pump Inhibitors and Clopidogrel
JAMA,
July 1, 2009;
302(1):
30 - 30.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. B Norgard, K. D Mathews, and G. C Wall
Drug-Drug Interaction Between Clopidogrel and the Proton Pump Inhibitors
Ann. Pharmacother.,
July 1, 2009;
43(7):
1266 - 1274.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. H. Friesen
Interaction between clopidogrel and proton pump inhibitors
Can. Med. Assoc. J.,
June 9, 2009;
180(12):
1228 - 1228.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The year in interventional cardiology.
J. Am. Coll. Cardiol.,
June 2, 2009;
53(22):
2080 - 2097.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Price
Bedside Evaluation of Thienopyridine Antiplatelet Therapy
Circulation,
May 19, 2009;
119(19):
2625 - 2632.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. F. Ford
Clopidogrel Resistance: Pharmacokinetic or Pharmacogenetic?
J. Clin. Pharmacol.,
May 1, 2009;
49(5):
506 - 512.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. M. Roden and C. M. Stein
Clopidogrel and the Concept of High-Risk Pharmacokinetics
Circulation,
April 28, 2009;
119(16):
2127 - 2130.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. R. Desai, J. L. Mega, S. Jiang, C. P. Cannon, and M. S. Sabatine
Interaction between cigarette smoking and clinical benefit of clopidogrel.
J. Am. Coll. Cardiol.,
April 14, 2009;
53(15):
1273 - 1278.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Desta, A. Modak, P. D. Nguyen, S. M. Lemler, Y. Kurogi, L. Li, and D. A. Flockhart
Rapid Identification of the Hepatic Cytochrome P450 2C19 Activity Using a Novel and Noninvasive [13C]Pantoprazole Breath Test
J. Pharmacol. Exp. Ther.,
April 1, 2009;
329(1):
297 - 305.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. C. Lau and P. A. Gurbel
The drug-drug interaction between proton pump inhibitors and clopidogrel
Can. Med. Assoc. J.,
March 31, 2009;
180(7):
699 - 700.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. N. Juurlink, T. Gomes, D. T. Ko, P. E. Szmitko, P. C. Austin, J. V. Tu, D. A. Henry, A. Kopp, and M. M. Mamdani
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel
Can. Med. Assoc. J.,
March 31, 2009;
180(7):
713 - 718.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Sourgounis, J. Lipiecki, T. S. Lo, and M. Hamon
Coronary Stents and Chronic Anticoagulation
Circulation,
March 31, 2009;
119(12):
1682 - 1688.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. M. Ho, T. M. Maddox, L. Wang, S. D. Fihn, R. L. Jesse, E. D. Peterson, and J. S. Rumsfeld
Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome
JAMA,
March 4, 2009;
301(9):
937 - 944.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. N. DeMaria, O. Ben-Yehuda, J. J. Bax, G. K. Feld, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, S. M. Narayan, D. J. Sahn, et al.
Highlights of the Year in JACC 2008.
J. Am. Coll. Cardiol.,
January 27, 2009;
53(4):
373 - 398.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Freedman and E. M. Hylek
Clopidogrel, Genetics, and Drug Responsiveness
N. Engl. J. Med.,
January 22, 2009;
360(4):
411 - 413.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Simon, C. Verstuyft, M. Mary-Krause, L. Quteineh, E. Drouet, N. Meneveau, P. G. Steg, J. Ferrieres, N. Danchin, L. Becquemont, et al.
Genetic Determinants of Response to Clopidogrel and Cardiovascular Events
N. Engl. J. Med.,
January 22, 2009;
360(4):
363 - 375.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Gladding, M. Webster, I. Zeng, H. Farrell, J. Stewart, P. Ruygrok, J. Ormiston, S. El-Jack, G. Armstrong, P. Kay, et al.
The Pharmacogenetics and Pharmacodynamics of Clopidogrel Response: An Analysis From the PRINC (Plavix Response in Coronary Intervention) Trial
J. Am. Coll. Cardiol. Intv.,
December 1, 2008;
1(6):
620 - 627.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. S. Kleiman
Searching for the Ceiling: New Reflections on the Disposition and Metabolism of Clopidogrel
J. Am. Coll. Cardiol. Intv.,
December 1, 2008;
1(6):
628 - 630.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Aleil, L. Jacquemin, F. De Poli, M. Zaehringer, J.-P. Collet, G. Montalescot, J.-P. Cazenave, M.-C. Dickele, J.-P. Monassier, and C. Gachet
Clopidogrel 150 mg/day to Overcome Low Responsiveness in Patients Undergoing Elective Percutaneous Coronary Intervention: Results From the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) Randomized Study
J. Am. Coll. Cardiol. Intv.,
December 1, 2008;
1(6):
631 - 638.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. S. Kleiman
Clopidogrel and Calcium-Channel Antagonists: Another Drug-Drug Interaction for the Ever-Wary Clinician?
J. Am. Coll. Cardiol.,
November 4, 2008;
52(19):
1564 - 1566.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. L. Bhatt, J. Scheiman, N. S. Abraham, E. M. Antman, F. K.L. Chan, C. D. Furberg, D. A. Johnson, K. W. Mahaffey, E. M. Quigley, R. A. Harrington, et al.
ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents
J. Am. Coll. Cardiol.,
October 28, 2008;
52(18):
1502 - 1517.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Writing Committee Members, D. L. Bhatt, J. Scheiman, N. S. Abraham, E. M. Antman, F. K.L. Chan, C. D. Furberg, D. A. Johnson, K. W. Mahaffey, and E. M. Quigley
ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents
Circulation,
October 28, 2008;
118(18):
1894 - 1909.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. P. Giugliano and E. Braunwald
The Year in Non-ST-Segment Elevation Acute Coronary Syndrome
J. Am. Coll. Cardiol.,
September 23, 2008;
52(13):
1095 - 1103.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Gilard, J.-C. Cornily, and J. Boschat
Reply
J. Am. Coll. Cardiol.,
September 16, 2008;
52(12):
1039 - 1039.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Pezalla, D. Day, and I. Pulliadath
Initial Assessment of Clinical Impact of a Drug Interaction Between Clopidogrel and Proton Pump Inhibitors
J. Am. Coll. Cardiol.,
September 16, 2008;
52(12):
1038 - 1039.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Does Omeprazole Affect Antiplatelet Therapy?
Journal Watch (General),
March 13, 2008;
2008(313):
8 - 8.
[Full Text]
|
 |
|

|
 |

|
 |
 
Clopidogrel, Omeprazole, and Upper GI Bleeding
Journal Watch Gastroenterology,
March 7, 2008;
2008(307):
6 - 6.
[Full Text]
|
 |
|

|
 |

|
 |
 
Identification of an Omeprazole-Clopidogrel Interaction
Journal Watch Cardiology,
February 20, 2008;
2008(220):
2 - 2.
[Full Text]
|
 |
|

|
 |

|
 |
 
P. A. Gurbel, W. C. Lau, and U. S. Tantry
Omeprazole: A Possible New Candidate Influencing the Antiplatelet Effect of Clopidogrel
J. Am. Coll. Cardiol.,
January 22, 2008;
51(3):
261 - 263.
[Full Text]
[PDF]
|
 |
|
|